^
Association details:
| Biomarker: | INPP4b deletion |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | gemcitabine (DNA synthesis inhibitor) + docetaxel (Tubulin polymerization promoter, Microtubule stabilizer) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract P2-10-02: Basal biomarkers nestin and INPP4b predict gemcitabine benefit in metastatic breast cancer: Results from the phase III SBG0102 clinical trial
Excerpt:
The IHC-basal patients did much better on the GD vs. the D arm (HR=0.36, 95% CI: 0.19-0.68) whereas there was no such difference in outcomes for other patients (HR=0.99). The interaction test was significant (p-interaction<0.005)....In the metastatic setting, women with IHC-basal breast cancers...have superior overall survival when randomized to gemcitabine-containing chemotherapy compared to docetaxel alone.
DOI:
10.1158/1538-7445.SABCS17-P2-10-02
